Nurix Therapeutics, Inc.: Form 10-Q for the period ended May 31, 2025
Filed with the SEC on Jul 9, 2025 and accepted by EDGAR at Jul 9, 2025, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-03-01 to 2025-05-31 | $44.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-12-01 to 2025-05-31 | $62.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2025-03-01 to 2025-05-31 | $78.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-12-01 to 2025-05-31 | $147.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-03-01 to 2025-05-31 | −$48.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-12-01 to 2025-05-31 | −$111.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-03-01 to 2025-05-31 | $760.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-12-01 to 2025-05-31 | $760.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-03-01 to 2025-05-31 | −$43.5m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-12-01 to 2025-05-31 | −$99.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-03-01 to 2025-05-31 | −$0.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-12-01 to 2025-05-31 | −$1.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-03-01 to 2025-05-31 | −$0.52 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-12-01 to 2025-05-31 | −$1.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-03-01 to 2025-05-31 | 83,882,477 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-12-01 to 2025-05-31 | 83,723,403 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-12-01 to 2025-05-31 | −$124.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-12-01 to 2025-05-31 | $6.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-05-31 | $84.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-05-31 | $515.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-05-31 | $591.6m | us-gaap:Assets |
| Current liabilities | At period end2025-05-31 | $75.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-05-31 | $144.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-05-31 | $447.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001549595-25-000095. Last ingested by Listed: Nov 5, 2026, 13:59 ET. Listed shows no prices and gives no investment advice.